Daratumumab/hyaluronidase Disease Interactions

The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy. It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.

The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.